– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today ...
– Data demonstrates that linaclotide reduces the need for rescue medications in this patient population – – Additional presentations further characterize the efficacy and safety profiles of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase III clinical trial of its 72 mcg dose of linaclotide in adults with chronic idiopathic ...
– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS remains the first-and-only FDA-approved ...
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – "With this license agreement, we have now preserved the majority of LINZESS patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results